Abstract

The present invention relates to antibody- and chemokine constructs against chemokine-receptor expressing cells, in particular against monocytes/macrophages expressing the chemokine receptor CCR5 and $CCR5^+$ T-cells. Furthermore, the invention relates to the use of antibody- and or chemokine constructs for the destruction of chemokine-receptor expressing cells for treating autoimmune diseases and allergic diseases, especially for treating chronic inflammatory joint diseases. The antibody- and chemokine constructs of the invention enable the directed depletion of chemokine-receptor expressing cells and thus a directed immunosuppressive therapy.